Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Butterfly Network, Inc. (NYSE: BFLY) announced it will report its first quarter 2023 financial results and provide a business update on May 11, 2023, prior to the market opening. The event will be followed by a conference call at 8:30 am ET, featuring key executives including CEO Joseph DeVivo and CFO Heather Getz. The call will be accessible via webcast on the company’s Investor Relations website and can also be joined by phone.
Butterfly, known for its revolutionary handheld ultrasound technology, aims to democratize medical imaging. The company’s focus on making ultrasound accessible globally aligns with its mission to enhance health equity. The innovative Butterfly iQ+ ultrasound device is now available to qualified healthcare practitioners across various regions worldwide.
Butterfly Network has appointed Joseph M. DeVivo as its new President and CEO, taking effect immediately. DeVivo brings over 35 years of experience in healthcare leadership, including a notable record at InTouch Health, where he achieved a 30% annual revenue growth and facilitated a $1.1 billion sale to Teladoc Health. He has also held significant positions at AngioDynamics and Smith and Nephew. DeVivo aims to enhance the accessibility of Butterfly's iQ+ ultrasound technology, making it as ubiquitous as the stethoscope. His appointment aligns with the company’s recent 510(k) clearance for an AI-enabled Auto B-line Counter, expected to launch in Summer 2023, which could revolutionize diagnostics in lung function evaluations.
Butterfly Network has announced the 510(k) clearance for its groundbreaking AI-enabled Auto B-line Counter, enhancing lung condition assessments. Utilizing deep learning technology, this new tool simplifies the evaluation of abnormal lung conditions by counting B-lines from a quick ultrasound clip, significantly speeding up diagnosis and treatment. The algorithm is trained on a dataset of over 3.5 million de-identified ultrasound images sourced from across the U.S. The company aims to launch this innovative solution in early summer 2023, aiming to improve healthcare accessibility and democratize medical imaging.